vs
派克汉尼汾（PH）与Stryker Corporation（SYK）财务数据对比。点击上方公司名可切换其他公司
Stryker Corporation的季度营收约是派克汉尼汾的1.4倍（$7.2B vs $5.2B），Stryker Corporation同比增速更快（11.4% vs 9.1%），Stryker Corporation自由现金流更多（$1.9B vs $768.0M），过去两年Stryker Corporation的营收复合增速更高（16.9% vs 1.0%）
派克汉尼汾（常简称为派克）是一家专注于运动与控制技术的美国企业，前身为派克电器公司，总部坐落于俄亥俄州大克利夫兰都市区的梅菲尔德高地，其技术及产品广泛应用于工业制造、航空航天等多个核心领域。
斯特赖克是一款八轮装甲战车，衍生自加拿大LAV III步兵战车，而后者源自瑞士莫瓦格食人鱼系列装甲车。该型战车由加拿大通用动力陆地系统公司为美国陆军生产，制造工厂位于安大略省伦敦市。它默认采用8×4四轮驱动，可切换为8×8全轮驱动模式。
PH vs SYK — 直观对比
营收规模更大
SYK
是对方的1.4倍
$5.2B
营收增速更快
SYK
高出2.3%
9.1%
自由现金流更多
SYK
多$1.1B
$768.0M
两年增速更快
SYK
近两年复合增速
1.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $7.2B |
| 净利润 | — | $849.0M |
| 毛利率 | 37.3% | 64.5% |
| 营业利润率 | 22.8% | 25.2% |
| 净利率 | — | 11.8% |
| 营收同比 | 9.1% | 11.4% |
| 净利润同比 | — | 55.5% |
| 每股收益（稀释后） | $6.60 | $2.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PHSYK
| Q4 25 | $5.2B | $7.2B | ||
| Q3 25 | $5.1B | $6.1B | ||
| Q2 25 | $5.2B | $6.0B | ||
| Q1 25 | $5.0B | $5.9B | ||
| Q4 24 | $4.7B | $6.4B | ||
| Q3 24 | $4.9B | $5.5B | ||
| Q2 24 | $5.2B | $5.4B | ||
| Q1 24 | $5.1B | $5.2B |
净利润PHSYK
| Q4 25 | — | $849.0M | ||
| Q3 25 | — | $859.0M | ||
| Q2 25 | $923.6M | $884.0M | ||
| Q1 25 | $961.2M | $654.0M | ||
| Q4 24 | $948.6M | $546.0M | ||
| Q3 24 | $698.5M | $834.0M | ||
| Q2 24 | $785.1M | $825.0M | ||
| Q1 24 | $726.7M | $788.0M |
毛利率PHSYK
| Q4 25 | 37.3% | 64.5% | ||
| Q3 25 | 37.5% | 63.6% | ||
| Q2 25 | 37.3% | 63.8% | ||
| Q1 25 | 36.9% | 63.8% | ||
| Q4 24 | 36.3% | 64.9% | ||
| Q3 24 | 36.8% | 64.0% | ||
| Q2 24 | 35.9% | 63.0% | ||
| Q1 24 | 35.4% | 63.6% |
营业利润率PHSYK
| Q4 25 | 22.8% | 25.2% | ||
| Q3 25 | 23.3% | 18.7% | ||
| Q2 25 | 22.7% | 18.5% | ||
| Q1 25 | 22.3% | 14.3% | ||
| Q4 24 | 20.9% | 9.0% | ||
| Q3 24 | 21.6% | 19.7% | ||
| Q2 24 | 21.1% | 19.4% | ||
| Q1 24 | 20.4% | 18.5% |
净利率PHSYK
| Q4 25 | — | 11.8% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | 17.6% | 14.7% | ||
| Q1 25 | 19.4% | 11.1% | ||
| Q4 24 | 20.0% | 8.5% | ||
| Q3 24 | 14.2% | 15.2% | ||
| Q2 24 | 15.1% | 15.2% | ||
| Q1 24 | 14.3% | 15.0% |
每股收益（稀释后）PHSYK
| Q4 25 | $6.60 | $2.20 | ||
| Q3 25 | $6.29 | $2.22 | ||
| Q2 25 | $7.16 | $2.29 | ||
| Q1 25 | $7.37 | $1.69 | ||
| Q4 24 | $7.25 | $1.41 | ||
| Q3 24 | $5.34 | $2.16 | ||
| Q2 24 | $6.06 | $2.14 | ||
| Q1 24 | $5.56 | $2.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $427.0M | $4.0B |
| 总债务越低越好 | $7.5B | — |
| 股东权益账面价值 | $14.3B | $22.4B |
| 总资产 | $30.5B | $47.8B |
| 负债/权益比越低杠杆越低 | 0.52× | — |
8季度趋势，按日历期对齐
现金及短期投资PHSYK
| Q4 25 | $427.0M | $4.0B | ||
| Q3 25 | $473.0M | $3.3B | ||
| Q2 25 | $467.0M | $2.4B | ||
| Q1 25 | $408.7M | $2.3B | ||
| Q4 24 | $395.5M | $3.7B | ||
| Q3 24 | $371.1M | $3.9B | ||
| Q2 24 | $422.0M | $1.9B | ||
| Q1 24 | $415.5M | $2.3B |
总债务PHSYK
| Q4 25 | $7.5B | — | ||
| Q3 25 | $7.5B | — | ||
| Q2 25 | $7.5B | — | ||
| Q1 25 | $7.4B | — | ||
| Q4 24 | $6.7B | — | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $7.2B | — | ||
| Q1 24 | $7.3B | — |
股东权益PHSYK
| Q4 25 | $14.3B | $22.4B | ||
| Q3 25 | $13.8B | $21.8B | ||
| Q2 25 | $13.7B | $21.2B | ||
| Q1 25 | $13.4B | $20.9B | ||
| Q4 24 | $13.1B | $20.6B | ||
| Q3 24 | $12.9B | $20.1B | ||
| Q2 24 | $12.1B | $19.8B | ||
| Q1 24 | $11.6B | $19.2B |
总资产PHSYK
| Q4 25 | $30.5B | $47.8B | ||
| Q3 25 | $30.7B | $47.1B | ||
| Q2 25 | $29.5B | $46.3B | ||
| Q1 25 | $28.9B | $46.0B | ||
| Q4 24 | $28.3B | $43.0B | ||
| Q3 24 | $29.6B | $43.8B | ||
| Q2 24 | $29.3B | $39.1B | ||
| Q1 24 | $29.6B | $39.4B |
负债/权益比PHSYK
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.59× | — | ||
| Q1 24 | 0.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $862.0M | $2.1B |
| 自由现金流经营现金流 - 资本支出 | $768.0M | $1.9B |
| 自由现金流率自由现金流/营收 | 14.8% | 26.1% |
| 资本支出强度资本支出/营收 | 1.8% | 3.7% |
| 现金转化率经营现金流/净利润 | — | 2.52× |
| 过去12个月自由现金流最近4个季度 | $3.3B | $4.3B |
8季度趋势，按日历期对齐
经营现金流PHSYK
| Q4 25 | $862.0M | $2.1B | ||
| Q3 25 | $782.0M | $1.5B | ||
| Q2 25 | $1.5B | $1.1B | ||
| Q1 25 | $630.0M | $250.0M | ||
| Q4 24 | $934.8M | $1.9B | ||
| Q3 24 | $744.0M | $1.5B | ||
| Q2 24 | $1.2B | $633.0M | ||
| Q1 24 | $795.1M | $204.0M |
自由现金流PHSYK
| Q4 25 | $768.0M | $1.9B | ||
| Q3 25 | $693.0M | $1.4B | ||
| Q2 25 | $1.3B | $928.0M | ||
| Q1 25 | $542.4M | $127.0M | ||
| Q4 24 | $813.6M | $1.7B | ||
| Q3 24 | $648.7M | $1.3B | ||
| Q2 24 | $1.1B | $481.0M | ||
| Q1 24 | $715.9M | $37.0M |
自由现金流率PHSYK
| Q4 25 | 14.8% | 26.1% | ||
| Q3 25 | 13.6% | 22.3% | ||
| Q2 25 | 25.5% | 15.4% | ||
| Q1 25 | 10.9% | 2.2% | ||
| Q4 24 | 17.2% | 25.9% | ||
| Q3 24 | 13.2% | 23.7% | ||
| Q2 24 | 21.6% | 8.9% | ||
| Q1 24 | 14.1% | 0.7% |
资本支出强度PHSYK
| Q4 25 | 1.8% | 3.7% | ||
| Q3 25 | 1.8% | 3.1% | ||
| Q2 25 | 2.5% | 3.0% | ||
| Q1 25 | 1.8% | 2.1% | ||
| Q4 24 | 2.6% | 4.1% | ||
| Q3 24 | 1.9% | 3.1% | ||
| Q2 24 | 2.3% | 2.8% | ||
| Q1 24 | 1.6% | 3.2% |
现金转化率PHSYK
| Q4 25 | — | 2.52× | ||
| Q3 25 | — | 1.79× | ||
| Q2 25 | 1.59× | 1.26× | ||
| Q1 25 | 0.66× | 0.38× | ||
| Q4 24 | 0.99× | 3.54× | ||
| Q3 24 | 1.07× | 1.77× | ||
| Q2 24 | 1.58× | 0.77× | ||
| Q1 24 | 1.09× | 0.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PH
| Filtration And Engineered Materials | $1.5B | 28% |
| Other | $1.1B | 22% |
| Motion Systems | $893.0M | 17% |
| Commercial Aftermarket | $619.0M | 12% |
| Commercial Original Equipment Manufacturer | $561.0M | 11% |
| Defense Original Equipment Manufacturer | $305.0M | 6% |
| Defense Aftermarket | $221.0M | 4% |
SYK
| Medical | $1.3B | 18% |
| Endoscopy | $1.1B | 16% |
| Traumaand Extremities | $1.1B | 15% |
| Instruments | $925.0M | 13% |
| Knees | $749.0M | 10% |
| Neuro Cranial | $669.0M | 9% |
| Neurovascular | $539.0M | 8% |
| Hips | $499.0M | 7% |
| Other Orthopaedics | $267.0M | 4% |
| Spine | $8.0M | 0% |
